Myeloma UK has a history of driving innovative trials in the UK to support patient access to early drugs and treatments. From 2009 – 2018 the Myeloma UK Clinical Trials Network resulted in the delivery of ten early phase clinical trials. Over 1000 patients at more than 40 different sites have taken part.
The establishment of the UK Myeloma Research Alliance-Myeloma UK–Concept and Access Research Programme (CARP) is a move to a sustainable trials programme.
CARP is the only initiative in the UK focused on the development of early phase trials to meet the needs of myeloma patients. The initiative focuses on designing trials and answering the questions which matter most to UK myeloma patients, carers and myeloma specialists. It also aims to put the UK at the forefront of myeloma research, so that patients here can get early access to experimental treatments.
Myeloma UK will fund a research grant totalling £846,682 over 3 years
This collaborative model combines the funding and patient insight from Myeloma UK, with the experience and expertise of the and the University of Leeds Clinical Trials Research Unit. These trials will either provide proof of concept data for larger and later phase trials, or data which can be used to support patients gaining access to treatments through the NHS.
The initiative will explore innovative trial designs such as ‘adaptive trials’, which allows researchers to learn from patient responses to treatment during the trial and gives them flexibility to adapt the treatment accordingly.
The funding is also an investment in myeloma clinical trial infrastructure. The Initiative will help support the further development of myeloma research capacity in the UK and keep the UK at the forefront of myeloma research. It also provides an opportunity for early career researchers or clinicians seeking trials experience to get advice and develop their skills with the expertise and support of the UK Myeloma Research Alliance and the University of Leeds Clinical Trials Research Unit.
The UKMRA-Myeloma UK-CARP will help improve myeloma treatments, innovate myeloma research and give UK myeloma patients access to new treatments or treatment combinations as part of trials.